2 May 2018 - Janssen today announced that NICE has issued its Final Appraisal Determination recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis.

The NICE recommendation states that guselkumab is recommended as an option for treating plaque psoriasis in adults, only if:

• the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
  
• the disease has not responded to other systemic therapies, including cyclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated and
  
• the company provides the drug with the discount agreed in the patient access scheme.
  

As part of the fast track appraisal procedure, NICE issued a FAD rather than an Appraisal Consultation Document, speeding up the process by which eligible patients will be able to access guselkumab.

Read Janssen press release